C12N 15/85
For animal cells
Official title: for animal cells
C12N15/85 (For animal cells) appears on 13,845 US grants and 24,924 published applications in this corpus.
Search patents in C12N- Granted patents
- 13,845
- Published applications
- 24,924
- Assignees
- 6,171
- Inventors
- 36,790
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1983 | 3 | 0 |
| 1984 | 1 | 0 |
| 1985 | 2 | 0 |
| 1986 | 5 | 0 |
| 1987 | 9 | 0 |
| 1988 | 16 | 0 |
| 1989 | 17 | 0 |
| 1990 | 33 | 0 |
| 1991 | 37 | 0 |
| 1992 | 67 | 0 |
| 1993 | 78 | 0 |
| 1994 | 76 | 0 |
| 1995 | 68 | 0 |
| 1996 | 149 | 0 |
| 1997 | 285 | 0 |
| 1998 | 419 | 0 |
| 1999 | 393 | 0 |
| 2000 | 355 | 0 |
| 2001 | 376 | 90 |
| 2002 | 339 | 650 |
| 2003 | 352 | 889 |
| 2004 | 279 | 701 |
| 2005 | 226 | 696 |
| 2006 | 304 | 690 |
| 2007 | 284 | 503 |
| 2008 | 254 | 509 |
| 2009 | 277 | 563 |
| 2010 | 310 | 630 |
| 2011 | 259 | 586 |
| 2012 | 315 | 507 |
| 2013 | 309 | 557 |
| 2014 | 387 | 688 |
| 2015 | 407 | 601 |
| 2016 | 433 | 683 |
| 2017 | 445 | 737 |
| 2018 | 455 | 863 |
| 2019 | 498 | 1309 |
| 2020 | 631 | 1452 |
| 2021 | 678 | 1499 |
| 2022 | 755 | 1789 |
| 2023 | 776 | 1861 |
| 2024 | 761 | 2107 |
| 2025 | 948 | 2136 |
| 2026 | 774 | 1628 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Preventing and treating amyloid-beta deposition by stimulation of innate immunity6 Oct 2026US 12,751,964 B2New York University
- Methods and materials for ameliorating creatine deficiency disorders6 Oct 2026US 12,751,995 B2The Regents of the University of California
- BCMA chimeric antigen receptors6 Oct 2026US 12,752,006 B2Regeneron Pharmaceuticals, Inc.
- Engineered meganucleases having specificity for a recognition sequence in the hydroxyacid oxidase 1 gene6 Oct 2026US 12,752,019 B2Precision BioSciences, Inc.
- Microdystrophin nucleic acid gene therapy constructs and uses thereof6 Oct 2026US 12,752,020 B2REGENXBIO Inc.
- Transgenic model of human cardiomyopathy8 Oct 2026US 2026/0305586 A1Stichting Genetische Hartspierziekte PLN
- Targeted Immune Cell Therapy Utilizing TRAIL and TNF Mediated Apoptosis8 Oct 2026US 2026/0306542 A1Northeastern University
- Treating a type i interferon upregulation or aberrant il-33 upregulation disease or condition with polyomavirus8 Oct 2026US 2026/0306609 A1The General Hospital Corporation
- Systems and Methods for Delivery of Viral Antigens8 Oct 2026US 2026/0306610 A1Veergen Inc.
- Vaccine Adjuvants8 Oct 2026US 2026/0306623 A1Seqirus Inc.
Most cited
By later US patents
- Ransgenic non-human animals for producing heterologous antibodies1,941US 5,545,806 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies of various isotypes1,748US 5,569,825 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies1,680US 5,633,425 AGenPharm International, Inc. · 1997
- Transgenic non-human animals for producing heterologous antibodies1,604US 5,625,126 AGenPharm International, Inc. · 1997
- Production of antibodies from transgenic animals1,567US 5,545,807 AMedical Research Council · 1996